A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia

Abstract Background Dyslipidemia is one of the most frequently implicated risk factors for development of atherosclerosis. This study evaluated the efficacy of amla (Emblica officinalis) extract (composed of polyphenols, triterpenoids, oils etc. as found in the fresh wild amla fruit) in patients wit...

Full description

Bibliographic Details
Published in:BMC Complementary and Alternative Medicine
Main Authors: Haridas Upadya, S. Prabhu, Aravinda Prasad, Deepa Subramanian, Swati Gupta, Ajay Goel
Format: Article
Language:English
Published: BMC 2019-01-01
Subjects:
Emblica officinalis
Cholesterol
AIP
TG, CoQ10
Dyslipidemia
Online Access:http://link.springer.com/article/10.1186/s12906-019-2430-y

Internet

http://link.springer.com/article/10.1186/s12906-019-2430-y

Similar Items